Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$29.5 million.

  • Vanda Pharmaceuticals' Free Cash Flow fell 135342.2% to -$29.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$110.4 million, marking a year-over-year decrease of 57975.63%. This contributed to the annual value of -$110.4 million for FY2025, which is 57975.63% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Free Cash Flow stood at -$29.5 million for Q4 2025, which was down 135342.2% from -$31.8 million recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Free Cash Flow peaked at $31.8 million during Q1 2023, and registered a low of -$33.6 million during Q1 2025.
  • In the last 5 years, Vanda Pharmaceuticals' Free Cash Flow had a median value of $970000.0 in 2022 and averaged -$965100.0.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Free Cash Flow surged by 80804.69% in 2021, and later crashed by 135342.2% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Free Cash Flow stood at $26.5 million in 2021, then tumbled by 65.43% to $9.2 million in 2022, then crashed by 143.54% to -$4.0 million in 2023, then soared by 49.03% to -$2.0 million in 2024, then plummeted by 1353.42% to -$29.5 million in 2025.
  • Its last three reported values are -$29.5 million in Q4 2025, -$31.8 million for Q3 2025, and -$15.6 million during Q2 2025.